EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC-ND 4.0

Beyond the protocol: navigating ethics and governance in the multicentre implementation trials – the QASC Australasia and T3 Trials

Simeon Dale iD, Sawsan Saheb, Oyebola Fasugba iD, Kelly Coughlan iD, Elizabeth McInnes iD, Dominique A Cadilhac iD, Ngai W Cheung iD, Kelvin Hill, Kirsty Page, Estela Sanjuan Menendez iD, Emily Neal, Vivien Pollnow und 7 weitere

Australian Health Review · 03.09.2026 · 50 (3)

DOI: 10.1071/ah26079 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Australian Health Review, online erschienen am 18.08.2026. Verfasst von Simeon Dale und 18 weiteren Autor:innen. Beteiligte Einrichtung: Nursing Research Institute - St Vincent's Health Network Sydney and St Vincent's Hospital Melbourne, Darlinghurst, NSW, Australia. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Multicenter Studies as Topic, Stroke. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To describe and compare ethics and governance approval timelines for the Quality in Acute Stroke Care (QASC) Australasia Trial (2021–present) and Triage, Treatment, and Transfer of Patients with Stroke in Emergency Departments (T3) Trial (2012–2014), benchmarking against national and international targets.

Methods

Retrospective, descriptive analysis of approval timelines for ethics, Site-Specific Assessment (SSA), Clinical Trials Research Agreements (CTRA), and Public Health Act (PHA) application (Queensland hospitals).

Results

The QASC Australasia Trial involved 52 Australian and 8 New Zealand hospitals. In Australia, lead ethics approval took 30 days. SSA approvals took a median of 91 days (interquartile range (IQR) 52–144). CTRA execution required a median of 56 days (IQR 38–105). PHA approval was required at 10 sites, with a median of 34 days (IQR 29–52). In New Zealand, ethics approval took 53 days. SSA approvals and CTRA execution took medians of 121 days (IQR 73–152) and 133 days (IQR 84–146), respectively. The T3 Trial involved 26 Australian hospitals. Lead ethics approval took 76 days. SSA approvals (n = 22) took a median of 132 days (IQR 106–175). Since the T3 Trial, Australian lead ethics approval times decreased by 61% and SSA approvals decreased by 31%. Only 33% of Australian QASC Australasia Trial and 5% of T3 Trial SSA approvals met the 60-day national benchmark.

Conclusions

Multicentre trial governance processes remain lengthy, particularly for New Zealand. CTRA and jurisdiction requirements delayed SSA approval. Streamlined processes are needed to optimise resources and accelerate evidence translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicMulticenter Studies as TopicStrokeHumansAustralasiaAustraliaBenchmarkingEmergency Service, HospitalNew ZealandRetrospective Studies

Stichwörter der Autor:innen

AustraliaNew ZealandPublic Health Act (PHA) approvalapproval timelinesclinical trial research agreement (CTRA)human research ethics committee (HREC) approvalimplementation researchmulticentre researchresearch governancesite-specific assessment (SSA) approval

Autor:innen und Institutionen

  • Nursing Research Institute - St Vincent's Health Network Sydney and St Vincent's Hospital Melbourne, Darlinghurst, NSW, Australia.
  • School of Nursing, Midwifery and Paramedicine, Australian Catholic University, North Sydney, NSW, Australia.
  • Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Vic, Australia.
  • Stroke and Critical Care Theme, The Florey, University of Melbourne, Heidelberg, Vic, Australia.
  • Centre for Diabetes and Endocrinology Research, Westmead Hospital and University of Sydney, Camperdown, NSW, Australia.
  • Stroke Foundation, Sydney, NSW, Australia.

ORCID-Profile: Simeon Dale, Oyebola Fasugba, Kelly Coughlan, Elizabeth McInnes, Dominique A Cadilhac, Ngai W Cheung, Estela Sanjuan Menendez, Eileen Gilder, Nicola Straiton, Julia Slark, Annemarei Ranta, Sandy Middleton

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Dale, S., Saheb, S., Fasugba, O., Coughlan, K., McInnes, E., Cadilhac, D. A., Cheung, N. W., Hill, K., Page, K., Sanjuan Menendez, E., Neal, E., Pollnow, V., Gilder, E., Straiton, N., Holman, T., Slark, J., Ranta, A., Levi, C., & Middleton, S. (2026). Beyond the protocol: navigating ethics and governance in the multicentre implementation trials – the QASC Australasia and T3 Trials. Australian Health Review, 50(3). https://doi.org/10.1071/ah26079

Vancouver

Dale S, Saheb S, Fasugba O, Coughlan K, McInnes E, Cadilhac DA, et al. Beyond the protocol: navigating ethics and governance in the multicentre implementation trials – the QASC Australasia and T3 Trials. Australian Health Review. 2026;50(3). doi:10.1071/ah26079

BibTeX
@article{Dale2026,
  author = {Dale, Simeon and Saheb, Sawsan and Fasugba, Oyebola and Coughlan, Kelly and McInnes, Elizabeth and Cadilhac, Dominique A and Cheung, Ngai W and Hill, Kelvin and Page, Kirsty and Sanjuan Menendez, Estela and Neal, Emily and Pollnow, Vivien and Gilder, Eileen and Straiton, Nicola and Holman, Tessa and Slark, Julia and Ranta, Annemarei and Levi, Christopher and Middleton, Sandy},
  title = {Beyond the protocol: navigating ethics and governance in the multicentre implementation trials – the QASC Australasia and T3 Trials},
  journal = {Australian Health Review},
  year = {2026},
  volume = {50},
  number = {3},
  doi = {10.1071/ah26079}
}
Kostenlos starten →